Agenus expands adjuvant licence and grants right of first negotiation to GSK
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Agenus have amended their licence and manufacturing agreement covering Agenus' QS-21 Stimulon adjuvant to include additional rights for its use in GSK Biologicals' adjuvant systems. In addition, Agenus granted GSK the first right to negotiate for the purchase of Agenus or certain of its assets. The first right to negotiate will expire after five years.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.